Releases

Print

Releases

Date Title and Summary
Dec 04, 2018
9:38 AM CET
Corporate Releases
Lundbeck announces retirement of Anders Gersel Pedersen, EVP and Head of Research and Development
Nov 30, 2018
9:17 AM CET
Corporate Releases
Lundbeck and Otsuka report positive phase II data for the combination treatment of brexpiprazole and sertraline for the treatment of Post-Traumatic Stress Disorder (PTSD)
Nov 20, 2018
11:51 AM CET
Corporate Releases
Lundbeck increases its share capital by 6,574 shares (0.0033 % of outstanding shares) as a result of exercise of employee warrants
Nov 07, 2018
7:42 AM CET
Corporate Releases
Lundbeck realized 12% growth in revenue (local currencies) and 56% growth in EPS in 9M 2018. Guidance for FY2018 raised
Oct 25, 2018
10:34 AM EDT
Corporate Releases
Lundbeck updates on clinical phase III study for Lu AF35700 in Treatment-Resistant Schizophrenia
Sep 28, 2018
3:30 AM EDT
Corporate Releases
Takeda and Lundbeck submit New Drug Application (NDA) for vortioxetine in Japan for the treatment of Major Depressive Disorder (MDD)
Aug 08, 2018
5:09 AM UTC
Corporate Releases
Lundbeck realized 14% growth in revenue (local currencies) and 83% growth in EPS
Jul 02, 2018
8:41 AM CEST
Corporate Releases
Dr. Deborah Dunsire named new President and CEO of Lundbeck
Jun 25, 2018
7:00 AM CEST
Press Releases
Lundbeck starts clinical development of potential new treatment of Parkinson's disease
Jun 08, 2018
5:24 PM CEST
Corporate Releases
Positive clinical phase III results of vortioxetine in Japanese adults with Major Depressive Disorder

In order to comply with applicable regulation, press releases concerning a specific medicinal product are removed from our website within three weeks of publication. They can be retained upon request. Please contact us here.

Cookie Policy